Skip to content
All Podcasts – Lifestyle
Author:
Celcuity Inc.
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
October 8, 2026
Celcuity Appoints David Gryska To Its Board Of Directors
October 7, 2026
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
September 30, 2026
Celcuity To Participate in Upcoming Investor Conferences
September 1, 2026
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
August 6, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
July 30, 2026
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
July 14, 2026
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
June 3, 2026
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
June 3, 2026
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
June 2, 2026
1
2
Next Page
→